Waardenburg syndrome (WS) is a clinically and genetically heterogeneous disease accounting for >2% of the congenitally deaf population. It is characterized by deafness in association with pigmentary anomalies and various defects of neural crest-derived tissues. At least four types are recognized (WS1, WS2, WS3 and WS4) on the basis of clinical and genetic criteria. Two previously described families seemed to delineate a new subtype characterized by WS2 in conjunction with ocular albinism (OA). Since mutations in the MITF gene are responsible for some instances of WS2, we screened for mutations in one of the WS2-OA families and discovered a 1 bp deletion in exon 8 of MITF. OA previously has been associated with compound heterozygosity for a mutant TYR allele and the TYR R402Q allele, a functionally significant polymorphism that is associated with moderately reduced tyrosinase catalytic activity. In this family, all of the individuals with the OA phenotype are either homozygous or heterozygous for TYR R402Q , and heterozyous for the 1 bp deletion in MITF. This suggests that the WS2-OA phenotype may result from digenic interaction between a gene for a transcription factor (MITF) and a gene that it regulates (TYR).
INTRODUCTION
Waardenburg syndrome (WS) is characterized by pigmentary anomalies, deafness and various defects of neural crest-derived tissues (1) , and accounts for >2% of the congenitally deaf population (2) . Ever since the first description of WS, the full scope of its clinical features has been controversial as all features show considerable variation in expressivity and reduced penetrance, even within families. Dystopia canthorum, the lateral displacement of the inner canthi relative to the outer canthi, allows for the distinction between type 1 and type 2 Waardenburg syndrome (WS1, MIM 193500 and WS2, MIM 193510) (3) (4) (5) (6) . Dystopia canthorum is 97% penetrant in families with WS1, and its uniform absence defines a family as WS2. Additional specific clinical features define other types of WS, such as upper limb abnormalities in WS3 (MIM 148820) and aganglionic megacolon in WS4 (MIM 277580). Each of the clinical features of WS has been reported to segregate as a distinct entity in other families.
Several families have been reported in whom WS and ocular albinism (OA) appeared to co-segregate as a distinct genetic syndrome. Bard (7) described a family with features typical of WS2 as well as ocular albinism (OA). Because OA, which is usually either an autosomal recessive or an X-linked recessive disorder, was the most prominent presenting feature in this family showing apparent dominant inheritance, and because WS2 and OA occurred together in most affected family members, the author proposed that a single novel dominant disorder was segregating. A second WS family with apparent OA was described by Goldberg (8) . Lewis (9) reported a family with an apparent dominant form of OA associated with sensorineural deafness (MIM 103470), and suggested that Bard's family (7) had the same disorder.
So-called 'autosomal recessive ocular albinism' (AROA) is now known to represent clinically mild instances of oculocutaneous albinism type I (OCA1, MIM 203100) or oculocutaneous albinism type II (OCA2, MIM 203200), autosomal recessive disorders that result from mutations in the tyrosinase (TYR) or P genes, respectively (10, reviewed in ref. 11). In the case of tyrosinase-related AROA, Fukai et al. (12) showed that AROA can result from compound heterozygosity for a mutant allele of TYR and a polymorphic allele (TYR R402Q ) encoding a form of tyrosinase with reduced catalytic activity. Subsequent studies have shown that this is a very frequent cause of AROA (R.A. Spritz, unpublished data).
Some cases of WS2 are caused by mutations in the MITF gene (13) (14) (15) . The MITF protein is thought to be a transcription factor that regulates the TYR gene (16) (17) (18) , suggesting a possible link between WS2, resulting from a MITF mutation, and AROA, Below the pedigree is an ethidium bromide-stained gel showing the products of a PCR reaction using an allele-specific primer for the 1 bp deletion in MITF. Primers for the tetranucleotide marker D6S1040 were included in the reaction tube as a control. The lanes of the gel are aligned to correspond with the individual symbols from the pedigree above. The allele-specific product is 77 bp, and is generated only from DNA from individuals with features of WS2.
resulting from reduced tyrosinase function. Accordingly, we re-ascertained the family originally described by Bard (7) and screened for mutations in both the MITF and TYR genes. We find that both a mutant allele of MITF and a functionally significant polymorphism of TYR are segregating in the MSU11 family, probably accounting for the juxtaposition of WS2 and AROA.
RESULTS

Clinical features
In the MSU11 family, generation III has been described previously (7) (Fig. 1A) . All of these individuals were contacted again in 1993 and 1994, and new ophthalmalogical and audiological evaluations made of III-3, who had exhibited the mildest pigmentary defects and no visual acuity defects. In addition, evaluations were made of individuals II-3 and II-4, who had not been described fully (7) , and individuals in generation IV, all of whom were born after 1978. A summary of findings is presented in Table 1 .
Conventional audiological evaluations were conducted in sound-proof booths. All of the deafness occurring in MSU11 is sensorineural and congenital, except for evidence of presbycusis in the left ear of II-3 and presbycusis overlying mild congenital deafness in the right ear of III-7.
Heterochromia irides is a prominent feature of the generation III sibship, in which both segmental iris bicolor and complete heterochromia occur ( Fig. 2A and B) . No instances of heterochromia occur in generation IV. Individual II-3 has mottled gray and green irides. Slit lamp examinations were performed on the sibship in generation III (7) and individual IV-4, and all except III-3 showed transillumination defects of the iris. Hypopigmentation of the fundus was mild and limited to the periphery in III-3, moderate in III-4 and III-5, and most severe in the twins III-6 and III-7 (7). Individual IV-4 had a defect of the right eye in which the pupil was both eccentrically located (corectopia) and elliptically shaped (dyscoria) (Fig. 2C ). She had a hypopigmented retina, thin irides and Brushfield spots. She was also photophobic, and is likely to have a vestibular defect. None of the individuals in MSU11 had dystopia canthorum.
Visual acuity defects in generation III were described by Bard (7) . With the exception of III-3, all individuals had strabismus and visual acuity defects ranging from 20/40 (III-4) to 20/200 (III-7). Visual acuity defects were not apparent in IV-1, -2, -3 or -5. Individual IV-4 had a slight visual acuity defect (right eye 20/50, left eye 20/40) and strabismus. Individual IV-6 had strabismus, but no additional ophthalmological data could be obtained (Fig. 2D) .
Individual III-4 exhibited a prominent white forelock ( Fig. 2A) , which is characteristic of Waardenburg syndrome (1). All of the sibs in generation III and IV have very fair complexions and light colored hair.
MITF and TYR genotypes
Single strand conformation polymorphism (SSCP) and DNA sequence analyses of the MITF gene of individual IV-4 demonstrated a heterozygous 1 bp deletion within exon 8 (Fig. 2E ). This deletion, in codon 275, results in a frameshift and brings a TGA termination codon into frame in exon 9.
The occurrence of this frameshift mutation in genomic DNA from affected individuals was confirmed by allele-specific PCR using a primer with a 3′ end corresponding to the mutant sequence. Under moderately stringent annealing conditions, a 77 bp PCR product was obtained only from DNA of individuals with unambiguous WS2 phenotypes (Fig. 1B) . Several individuals are either heterozygous or homozygous for the TYR R402Q allele (Table 1) (Fig. 3) . Of special note are individuals III-4, -5 and -7, all of whom are doubly heterozygous for the mutant MITF allele and the TYR R402Q polymorphism, and all of whom exhibit ocular albinism. Individuals III-3, III-6, IV-4, IV-5 and IV-6 are all homozygous for TYR R402Q . Individual III-3, who has two normal MITF alleles, was considered to be 'affected' by Bard (7) on the basis of slight hypopigmentation of the periphery of the retina alone. However, he would probably never have been ascertained if not for his severely affected sibs, and our subsequent re-evaluation showed no ophthalmological abnormalities at all. In light of these findings, we reclassify individual III-3 as normal. We have little clinical information for individual IV-5, who is also homozygous normal for MITF, but he reportedly has normal hearing and normal visual acuity. The remaining TYR-R402Q homozygotes have the most severe visual acuity and hearing deficits of any of the individuals who are also heterozygous for the MITF mutant allele.
DISCUSSION
WS is a clinically and genetically heterogeneous group of pigmentation-deafness disorders caused, in part, by mutations in the transcription factor genes PAX3 (WS1 and WS3) and MITF (WS2) (13) (14) (15) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . All of the clinical features of WS show reduced penetrance and variable expressivity, even within families segregating a single mutation. This observation suggests that genetic background may play a major role in the etiology of some of the clinical attributes of these syndromes in both human (32) (33) (34) and murine (35) models of WS.
Pandya et al. (33) recently posited an oligogenic epistasis model of WS in which clinical features involve genes in a 'melanocyte cluster'. Under this model, inter-and intra-family variability in WS could result from different combinations of mutations in genes for receptors and their ligands, or for transcription factors and their target genes, within the 'melanocyte cluster'. Thus, the most important background genes that modulate the clinical features of WS may be those whose expression is regulated directly by the PAX3 or MITF transcription factors. The MITF protein is thought to regulate the expression of various pigmentation genes by binding at a promoter element termed the M-box (17) . In particular, MITF has been shown to transactivate the promoter of the tyrosinase gene TYR (16, 36) , which encodes the rate-limiting enzyme of melanin biosynthesis.
The MITF mutation segregating in MSU11 is a one base deletion in exon 8, which shifts the reading frame and results in a premature translational termination codon in exon 9. Transcripts with premature translational termination are often degraded by mechanisms not yet fully understood (37) . However, transcripts containing nonsense or frameshift mutations in their final exon may escape this nonsense RNA decay mechanism. One example of this is a frameshift in the final exon of the β-globin gene that results in a mild, dominant-negative form of β-thalassemia (38) . The MITF frameshift described in this study is unlike other MITF mutations in that translational termination is predicted to occur within exon 9, the last translated exon. It is possible that the corresponding truncated protein product might have novel transactivation capabilities, perhaps accounting for the OA phenotype in association with WS2. However, truncated MITF proteins expressed from mutant cDNA constructs fail to transactivate the TYR promoter, and fail to dimerize with normal MITF protein (15) , suggesting that the hypothetical truncated MITF protein polypeptide resulting from the exon 8 frameshift described here is very unlikely to act in a dominant-negative manner, at least with regard to regulation of the TYR gene. It seems more likely that the MITF exon 8 frameshift results in haploinsufficiency of MITF function, with consequent down-regulation of TYR gene expression.
Homozygosity for mutations in the TYR gene results in greatly reduced tyrosinase catalytic activity and OCA1. Most individuals with OCA1 are compound heterozygotes for two different mutant alleles of TYR (10, 11) . OCA1 shows considerable phenotypic overlap with AROA. Individuals with tyrosinase-related AROA typically are compound heterozygotes for a mutant allele of TYR and a polymorphic allele (TYR R402Q ) encoding a form of tyrosinase with reduced catalytic activity-although still within the normal range (12) . Heterozygotes and even homozygotes for TYR R402Q are phenotypically normal (39) , whereas compound heterozygotes for OCA1 mutant alleles and TYR R402Q may manifest AROA (12) . Nevertheless, most OCA1/ TYR R402Q Figure 3 . Representative sequencing autoradiograph illustrating the band patterns associated with three possible TYR genotypes. Direct sequencing of PCR-amplified products generated from genomic DNA reveal, from left to right, homozygosity for Gln402; heterozygosity for Gln402 and Arg402; and homozygosity for Arg402. An ideogram at the right illustrates the banding pattern for a heterozygote.
compound heterozygotes are also phenotypically normal, underscoring the importance of epistatic phenomena that modulate the pigmentary phenotype.
The TYR R402Q polymorphism is segregating in the MSU11 family, as is a mutant allele of the MITF gene. Several members of the MSU11 family are affected not only with WS2, but with OA-a feature not usually associated with WS2. Moreover, OA usually segregates as an autosomal recessive condition, as stated above. However, the individuals in MSU11 with OA are actually heterozygous for the mutant MITF allele and either heterozygous or homozygous for the TYR R402Q polymorphism. By contrast, individuals who have two normal MITF alleles are phenotypically normal regardless of the TYR genotype. Even if the mutant alleles of MITF were expressed, the resulting proteins would be unlikely to transactivate the TYR promoter (15); thus, the occurrence of OA in the TYR R402Q /---individuals in MSU11 seems likely to be the result of down-regulation of the TYR locus through haploinsufficiency of MITF. If so, this would appear to be the first example of oligogenic, or in this case digenic, inheritance in WS.
MATERIALS AND METHODS
Preparation of genomic DNA
The family reported by Bard (7) (generations II and III in Fig. 1 ) were re-ascertained, and pedigree and clinical information collected regarding generation IV. We refer to this family as MSU11 (19) . Two 20 ml blood samples were collected from all available members of MSU11, and DNA was prepared as described (20) .
PCR amplification of the MITF and TYR genes
Each of the nine exons of MITF were PCR amplified from the genomic DNA as described by Tassabehji et al. (14) . The PCR products were radiolabeled with [α-33 P]CTP incorporated during the amplification reaction (40), diluted with 2 vols of sequencing loading buffer, denatured at 95_C for 5 min, and then electrophoresed through 0.5× MDE gels (AT Biochem) for SSCP analysis as described (21, 22) . A variant band was observed in exon 8 amplicons from individual MSU11-IV-4. These PCR products were cloned in pGEM-T (Promega) and sequenced using an ABI 373A DNA sequencer (Applied Biosystems).
To confirm the presence of the MITF mutation in genomic DNA, mutation-specific PCR was performed by substituting the primer (5′-AACCGACAGGAGAAACTGGG-3′) for the forward exon 8 PCR primer, and using the normal reverse primer (5′-CTGTTTCTACTGTCTTGAAGTCGG-3′). As a control, primers for tetranucleotide repeat marker D6S1040 were included in the reaction tube. The reaction conditions were: each primer 0.25 µM, each dNTP 100 µM, 1.5 mM MgCl 2 , 50 mM KCl, 1.5 U of thermostable DNA polymerase and 50 ng of genomic DNA in a total of 50 µl; cycled 30 times at 94_C (30 s)-55.5_C (45 s)-72_C (45 s) with a 5 min final extension at 72_C. The PCR products were resolved in 3% NuSeive 3:1 gels (FMC) and visualized by ethidium bromide staining. Under these conditions, constant bands of ∼250 bp, corresponding to the alleles of D6S1040, were observed in all individuals, while the mutant allele-specific band migrated at 77 bp. As an independent confirmation of genotype, the exon 8 PCR products with a 1 bp deletion were resolved from the normal PCR products on a sequencing gel for all individuals in MSU11 (data not shown).
Affected family members were screened for pathologic mutations of the TYR gene and were genotyped for the TYR R402Q allele by simultaneous SSCP/heteroduplex analysis using 0.5× MDE gels as described (41) . This method detects ∼95% of known TYR mutations. Furthermore, all members of MSU11 were genotyped directly for the TYR R402Q allele. PCR amplifications of TYR exon 4 were carried out as above using the primers 5′-ACATCTTTC-CATGTCTCCAG-3′ and 5′-ATTCAGCAATTCCTCTGA-AA-3′. The 350 bp PCR products were gel purified and then cycle sequenced in both directions using the n-Taq Cycle Sequencing kit (USB), [α-33 P]CTP and one or the other of the PCR primers.
